Fulgent Genetics, Inc. FLGT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s additional paid-in capital?
- Fulgent Genetics, Inc. (FLGT) reported additional paid-in capital of $540.14M in Q1 2026.
- How has Fulgent Genetics, Inc.'s additional paid-in capital changed year-over-year?
- Fulgent Genetics, Inc.'s additional paid-in capital decreased by 0.7% year-over-year, from $543.9M to $540.14M.
- What is the long-term trend for Fulgent Genetics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Fulgent Genetics, Inc.'s additional paid-in capital has grown at a 6.6% compound annual growth rate (CAGR), from $418.07M to $574.52M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.